Sandostatin Lar is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 10 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 13, 2017. Details of Sandostatin Lar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5922338 (Pediatric) | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan, 2017
(7 years ago) |
Expired
|
|
US5922682 (Pediatric) | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan, 2017
(7 years ago) |
Expired
|
| US5922338 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul, 2016
(8 years ago) |
Expired
|
| US5922682 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul, 2016
(8 years ago) |
Expired
|
|
US5688530 (Pediatric) | Sustained release formulations of water soluble peptides |
May, 2015
(9 years ago) |
Expired
|
|
US5639480 (Pediatric) | Sustained release formulations of water soluble peptides |
Dec, 2014
(10 years ago) |
Expired
|
| US5688530 | Sustained release formulations of water soluble peptides |
Nov, 2014
(10 years ago) |
Expired
|
| US5639480 | Sustained release formulations of water soluble peptides |
Jun, 2014
(10 years ago) |
Expired
|
|
US5538739 (Pediatric) | Sustained release formulations of water soluble peptides |
Jan, 2014
(10 years ago) |
Expired
|
| US5538739 | Sustained release formulations of water soluble peptides |
Jul, 2013
(11 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Sandostatin Lar and ongoing litigations to help you estimate the early arrival of Sandostatin Lar generic.
Sandostatin Lar's Litigations
Sandostatin Lar been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 05, 1995, against patent number US5922682. The petitioner , challenged the validity of this patent, with BRICH et al as the respondent. Click below to track the latest information on how companies are challenging Sandostatin Lar's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5922682 | April, 1995 |
Decision
(04 Jul, 1776) | BRICH et al | |
US patents provide insights into the exclusivity only within the United States, but Sandostatin Lar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sandostatin Lar's family patents as well as insights into ongoing legal events on those patents.
Sandostatin Lar's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Sandostatin Lar's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 13, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Sandostatin Lar Generic API suppliers:
Octreotide Acetate is the generic name for the brand Sandostatin Lar. 11 different companies have already filed for the generic of Sandostatin Lar, with Sun Pharm Inds having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Sandostatin Lar's generic
Alternative Brands for Sandostatin Lar
There are several other brand drugs using the same active ingredient (Octreotide Acetate) as Sandostatin Lar. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Chiesi |
| |
| Novartis |
| |
| Sun Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Octreotide Acetate, Sandostatin Lar's active ingredient. Check the complete list of approved generic manufacturers for Sandostatin Lar
About Sandostatin Lar
Sandostatin Lar is a drug owned by Novartis Pharmaceuticals Corp. Sandostatin Lar uses Octreotide Acetate as an active ingredient. Sandostatin Lar was launched by Novartis in 1998.
Approval Date:
Sandostatin Lar was approved by FDA for market use on 25 November, 1998.
Active Ingredient:
Sandostatin Lar uses Octreotide Acetate as the active ingredient. Check out other Drugs and Companies using Octreotide Acetate ingredient
Dosage:
Sandostatin Lar is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 10MG BASE/VIAL | INJECTABLE | Prescription | INJECTION |
| EQ 20MG BASE/VIAL | INJECTABLE | Prescription | INJECTION |
| EQ 30MG BASE/VIAL | INJECTABLE | Prescription | INJECTION |